Intellia Therapeutics Statistics
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
11.71-0.66 (-5.34%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics by the numbers
Intellia Therapeutics has a market capitalization of $1.64 billion based on 140.13M shares outstanding. With trailing EPS of $-3.35, Intellia Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 3.2% below its 50-day average and 9.2% below its 200-day average.
Average daily trading volume is 4.08M shares, or about $47.8 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
NTLA valuation vs. peer median
| Metric | NTLA | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.64B | $607.04M | +170% |
| Avg. volume | 4.08M | 1.36M | +199% |
Peer median across 8 companies: CLDX, QDEL, ACHV, NEOG, TKNO, MYGN, NNNN, IMDX.
Valuation
- Market cap
- $1.64B
- EPS (TTM)
- $-3.35
- Shares outstanding
- 140.13M
Price and trading
- Previous close
- 12.37
- Open
- 12.11
- Day range
- 11.70 – 12.41
- 52-week range
- 7.95 – 28.25
- 52-week change
- -42.71%
- Beta
- —
- Volume
- 8.27M
- Average volume
- 4.08M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 1.64B
- Forward Pe
- -4.56
- Eps
- -3.35
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 28.25
- Week52 Low
- 7.95
- Avg Volume
- 4.08M
- Shares Outstanding
- 140.13M
- Ma50
- 12.09
- Ma200
- 12.89
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -58.55%
- Pct From52w Low
- 47.30%